SCHEMBL13802434

SCHEMBL13802434

Cc1c(CC(=O)O)c2ccccc2n1CC1CCC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.53
PLA2G2A P14555 4/20 0.51
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
ABCB1 P08183 1/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
EGFR P00533 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
PLA2G1B P04054 1/20 0.45
PTGER4 P35408 1/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13802436 0.96 PLA2G2A (0.55) PTGDR2PLA2G2ATHRATHRBABCB1
SCHEMBL13802426 0.95 PTGDR2 (0.55) PTGDR2PLA2G2ATHRATHRBABCB1
SCHEMBL18294883 0.79 PTGER4 (0.47) PLA2G2ACNR2PTGER4NPC1
SCHEMBL18294880 0.79 PLA2G2A (0.48) PLA2G2ACNR1CNR2PTGER4NPC1
SCHEMBL7952544 0.78 PLA2G2A (0.82) PTGDR2PLA2G2AABCB1PTGS1PTGS2
SCHEMBL18294853 0.78 PLA2G2A (0.50) PLA2G2ACNR1CNR2PTGER4NPC1
SCHEMBL13802411 0.77 ABCB1 (0.56) PTGDR2PLA2G2AABCB1PTGS1PTGS2
SCHEMBL8174614 0.75 ABCC4 (0.41) PTGDR2THRATHRBABCB1PTGS1
SCHEMBL28174704 0.75 CNR2 (0.58) PTGDR2THRATHRBEGFRCNR1
SCHEMBL13802437 0.74 ABCB1 (0.56) PTGDR2PLA2G2AABCB1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 PTGDR2 2287/4885PLA2G2A 409/4885THRA 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.